Tag: KDC-MN-343

  • Dexmedetomidine

    Selective alpha-2A adrenergic agonist (anesthetic)

    A potent selective alpha-2A adrenergic agonist; an intravenous sedative producing arousable sedation without respiratory depression.

    Abstract

    Dexmedetomidine ((S)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; CAS 113775-47-6; molecular formula C13H16N2; molecular weight 200.28) is a highly selective alpha-2A adrenergic agonist developed at Farmos and approved by the FDA in 1999 (Precedex). The compound is the active S-enantiomer of medetomidine (used in veterinary anesthesia). Alpha-2A selectivity over alpha-2B and alpha-2C is approximately 8-fold; selectivity over alpha-1 is approximately 1620-fold, much higher than clonidine. The clinical profile is unique: the alpha-2A activation in the locus coeruleus produces sedation that mimics natural sleep architecture, with patients arousable on stimulation; respiratory drive is preserved. Approved indications: ICU sedation, procedural sedation, conscious sedation. Plasma half-life is approximately 2 hours; metabolism is hepatic. Used as the canonical highly selective alpha-2A agonist in anesthesia research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.